Abstract 165P
Background
The role of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) as an immune checkpoint has garnered significant interest in oncology, particularly in the context of non-small cell lung cancer (NSCLC). TIGIT inhibition represents a promising therapeutic strategy, potentially enhancing anti-tumor immunity. This meta-analysis aims to evaluate the clinical efficacy of TIGIT inhibitors in NSCLC and to explore the correlation between TIGIT expression and relevant biomarkers.
Methods
A comprehensive literature search was conducted in databases such as PubMed, Scopus, and clinical trial registries up to June 2024. Studies were included if they reported clinical outcomes of TIGIT inhibitors in NSCLC patients. Data extraction focused on progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profiles. Biomarker correlation analysis included TIGIT expression levels, PD-L1 status, and other immune-related markers. Statistical analysis involved pooled hazard ratios (HRs) for PFS and OS, and odds ratios (ORs) for ORR, with 95% confidence intervals (CIs).
Results
A total of 12 studies encompassing 1,750 patients were included. TIGIT inhibition showed a significant improvement in PFS (HR 0.73, 95% CI 0.61-0.87) and OS (HR 0.78, 95% CI 0.66-0.92) compared to standard treatments. The ORR was notably higher in the TIGIT inhibitor group (OR 1.45, 95% CI 1.21-1.73). Biomarker analysis revealed a positive correlation between high TIGIT expression and enhanced response rates. Additionally, patients with concurrent high PD-L1 expression demonstrated a synergistic benefit from TIGIT inhibition. The safety profile of TIGIT inhibitors was manageable, with no unexpected adverse events.
Conclusions
TIGIT inhibition offers a significant therapeutic benefit in NSCLC, improving survival outcomes and response rates. The correlation between TIGIT expression and clinical efficacy underscores the potential for biomarker-driven patient selection. These findings support further investigation and development of TIGIT inhibitors as a component of NSCLC treatment regimens.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract